Literature DB >> 23594005

Belimumab for systemic lupus erythematosus.

Bevra Hannahs Hahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23594005     DOI： 10.1056/NEJMct1207259

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  A case of central nervous system nocardiosis in a patient with lupus treated with belimumab.

Authors:  Richard Hc Lai; Deborah Kim; Florina Constantinescu
Journal:  Eur J Rheumatol       Date:  2016-12-01

Review 3.  Developments in therapy with monoclonal antibodies and related proteins.

Authors:  H Michael Shepard; Gail Lewis Phillips; Christopher D Thanos; Marc Feldmann
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

Review 4.  Skin-Associated B Cells in Health and Inflammation.

Authors:  Gudrun F Debes; Shannon E McGettigan
Journal:  J Immunol       Date:  2019-03-15       Impact factor: 5.422

Review 5.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

6.  Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.

Authors:  K A Nikolova-Ganeva; V V Gesheva; T A Todorov; R E Voll; T L Vassilev
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 7.  Rationale for B cell targeting in SLE.

Authors:  Iñaki Sanz
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

Review 8.  Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.

Authors:  Sara Guerreiro Castro; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-03-01       Impact factor: 5.346

9.  Small Molecule Inhibition of Rab7 Impairs B Cell Class Switching and Plasma Cell Survival To Dampen the Autoantibody Response in Murine Lupus.

Authors:  Tonika Lam; Dennis V Kulp; Rui Wang; Zheng Lou; Julia Taylor; Carlos E Rivera; Hui Yan; Qi Zhang; Zhonghua Wang; Hong Zan; Dmitri N Ivanov; Guangming Zhong; Paolo Casali; Zhenming Xu
Journal:  J Immunol       Date:  2016-10-14       Impact factor: 5.422

10.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.